Health Insurers Sink on Sanders’ Medicare for All Plan
US health insurance stocks experienced a significant downturn following announcements of new federal audits for Medicare and Senator Bernie Sanders' proposals for expanded Medicare eligibility. UnitedHealth Group Inc., the largest insurer, saw its shares drop by as much as 21%, wiping out almost all its year-to-date gains due to these developments.
Medicare Annual Enrollment Halftime Report: 75% of enrollees have used AI tools to review 2027 Medicare plans
A new eHealth report reveals that 75% of Medicare beneficiaries who reviewed their 2027 plan options utilized AI tools, although licensed insurance agents remain the primary choice for plan selection. The report also highlights a significant increase in Medicare Advantage plans offered by eHealth covering GLP-1 drugs for obesity and growing optimism about healthcare affordability post-mid-term elections, despite concerns about rising premiums and out-of-pocket costs.
Humana Drops 6.4% Amid Sector-Wide Selling
Humana Inc. shares fell 6.4% to $415.14, caught in a broad sector-wide selloff affecting managed care and health insurance stocks. The decline was not company-specific, as peers like UnitedHealth Group and Elevance Health also saw significant drops, suggesting broader market concerns rather than individual company issues. Despite the sharp decline, analyst sentiment remains constructive with no recent price target cuts, indicating that Wall Street's view of Humana's fundamentals has not materially shifted.
Cytokinetics chief legal officer sells $794,877 in shares
Jeffrey Hessekiel, Cytokinetics' Chief Legal & Admin Officer, sold 15,106 shares of the company's common stock for $794,877 to cover tax withholding obligations. This "sell to cover" transaction was mandated and not discretionary, occurring while the stock trades near its 52-week low. Despite recent strong Q3 2026 financial results, analysts and InvestingPro still consider the stock undervalued with optimistic price targets.
Humana Drops 8.5% Intraday: What the Selloff Looks Like
Humana (HUM) experienced an 8.5% intraday drop, falling from its $441.37 open to stabilize in the low $400s, an unusually sharp move for a large managed-care insurer. Competitor Clover Health (CLOV) also fell by 7.2%, suggesting an industry-wide event rather than company-specific news. Investors are closely watching whether the $401 intraday low will hold as a support level.
Humana Drops 6.4% Amid Sector-Wide Selling
Humana Inc. shares dropped 6.4% on Wednesday, reflecting a broad sector-wide selloff that impacted managed care and health insurance stocks like UnitedHealth Group, Elevance Health, Centene, Molina Healthcare, and Clover Health. The decline was not company-specific, suggesting broader concerns about the healthcare coverage sector rather than Humana's fundamentals. Despite the drop, analyst sentiment remains constructive, with no recent price target cuts.
Molina Healthcare Drops 5.9% Amid Sector-Wide Selling
Molina Healthcare's stock fell 5.9% on Wednesday, closing at $208.22, as part of a broad selloff impacting managed care companies. Major competitors like UnitedHealth Group, Humana, Centene, Elevance Health, and Clover Health also experienced significant declines, indicating a sector-wide retreat rather than company-specific issues for Molina. The synchronized drop suggests a shift in investor sentiment regarding the managed care industry's outlook or risk profile.
Few payers are ready for looming electronic prior authorization deadline
A new survey by the Workgroup for Electronic Data Interchange (WEDI) reveals that only 1 in 10 payers are fully prepared to implement the electronic prior authorization requirements mandated by a 2024 regulation, despite a January 1 deadline. Payers are facing significant challenges with system connectivity, workflow adaptation, and higher-than-anticipated costs for compliance with the API requirements. While most payers are at least halfway there, providers are also largely unprepared, highlighting the complexity and cost of the new interoperability rules.
UnitedHealth, Humana and Elevance fall sharply after Medicare audit proposal
UnitedHealth, Humana, and Elevance Health experienced significant stock declines following a CMS proposal to extend Medicare Advantage audit recoveries back to 2018. The proposal, which could amount to roughly $9 billion per payment year, led to a combined paper loss of about $43 billion for the three companies by early afternoon on November 18, 2026. Analysts expect potential legal challenges to the rule, with Oppenheimer suggesting recoveries may be concentrated later and priced into future bids.
This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Several Wall Street analysts have upgraded their ratings for five companies, including Millicom International Cellular S.A., SOLV Energy, Inc., CNX Resources Corporation, Tandem Diabetes Care, Inc., and Elevance Health, Inc. Notably, Argus Research analyst David Toung turned bullish on Elevance Health, upgrading it to Buy with a $510 price target. These upgrades reflect positive shifts in analyst outlooks, with revised price targets for most of the listed stocks.
Elevance Health Inc. stock outperforms competitors despite losses on the day
Shares of Elevance Health Inc. (ELV) declined by 7.63% to $400.84 on Wednesday, marking its second consecutive day of losses. This occurred despite a generally dismal trading session where the S&P 500 Index (SPX) fell 0.23% and the Dow Jones Industrial Average (DJIA) fell 1.11%. Despite the individual stock loss, the title suggests it outperformed competitors.
Wafd stock hits 52-week low at 28.1 USD
WaFd Inc.'s stock has fallen to a 52-week low of $28.10, reflecting decreased investor confidence and a 9.76% decline over the past year. Despite this, InvestingPro analysis suggests the stock is undervalued with a P/E ratio of 8.82 and a PEG ratio of 0.4, indicating potential for near-term earnings growth. The company also maintains a consistent dividend payment history for 44 consecutive years, offering a 3.82% yield.
Argus Research upgrades Elevance Health to Buy from Hold, sets price target at $510
Argus Research has upgraded Elevance Health (ELV) to Buy from Hold, setting a price target of $510. This target suggests a 17.5% upside from the stock's closing price of $433.93 on November 17. Recent analyst actions on Elevance Health have seen price targets ranging from $449 to $523 over the past month.
Florida Seniors and Primary Care Providers Agree that Prevention, Affordable Care and Comprehensive Coverage are Keys to Healthy Aging
Humana commissioned two Morning Consult surveys of Florida seniors and primary care providers, highlighting affordability, prevention, supplemental benefits, and coordinated care as top priorities for healthy aging. The surveys suggest strong retention for Medicare Advantage plans, with 97% of current enrollees planning to stay. However, both providers and seniors identified out-of-pocket and prescription drug costs as significant barriers.
Elevance Health upgraded by Argus
Elevance Health (ELV) has received an upgrade from Argus Research. This article provides historical context for ELV's stock performance following analyst upgrades and other headlines, noting that the stock closed higher 2 out of 3 times after an upgrade since January 2026. It also details the median stock movement after previous headlines and offers further resources for researching ELV.
Elevance Health upgraded by Argus
Argus Research has upgraded Elevance Health (ELV), leading to the stock closing higher in 2 out of 3 subsequent trading sessions after similar past upgrades. The article also provides historical context, showing that ELV's stock has had a median move of 1.6% after previous headlines. Investors can also access detailed historical trading data and analyst actions on Quantisnow.
UnitedHealth Shares Slide 5.4% Amid Scrutiny Over Conglomerate Structure and Medicare Oversight
UnitedHealth Group Inc. shares dropped 5.42% following renewed calls from Senator Elizabeth Warren to break up major healthcare conglomerates with the proposed Break Up Big Medicine Act. This legislative push, coupled with the Centers for Medicare & Medicaid Services proposing the CRUSH rule to tighten Medicare Advantage regulations, intensified scrutiny on UnitedHealth's integrated business model. Despite strong third-quarter earnings, the company's stock underperformed the market.
UnitedHealth Group falls 5.42% in Tuesday's session
UnitedHealth Group shares experienced a significant drop, trading 5.42% below their previous close at $389.68 on November 17, 2026. The company's market capitalization stood at $353.89 billion in the United States health care sector. This decline was reported after the market closed, with the last traded price differing from the exchange's official closing price.
Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments
The Centers for Medicare & Medicaid Services (CMS) has proposed significant program integrity reforms aimed at combating fraud, waste, and abuse across federal healthcare programs, potentially saving nearly $90 billion over the next decade. The "Comprehensive Regulations to Uncover Suspicious Healthcare" rule strengthens Medicare Advantage audits, mandates reporting of suspected fraud, and protects seniors from unwanted solicitations. Additionally, it tightens oversight for Medicaid and CHIP and prevents unauthorized enrollments in the Health Insurance Marketplace.
UnitedHealth's outside review praised how medical policies are written—but did not examine the denials patients actually experience
An outside review commissioned by UnitedHealth Group found that its insurance arm uses a strong, evidence-based process to write medical policies, but the review notably did not examine how these policies are applied to individual patients, including approval or denial of care. This omission is significant for patients and doctors who frequently dispute UnitedHealthcare's denial decisions. While the review praised the company's policy development, outside data from KFF and the HHS inspector general indicate high denial rates and overturn rates on appeal for UnitedHealthcare, suggesting a disconnect between policy quality and patient experience.
Warren Buffett Just Gave Away $5.5 Billion of Berkshire Stock Without Selling a Share. Here's His Rule for a 72-Year-Old With $400,000 in Berkshire Who Gives $20,000 a Year to Her Church
Warren Buffett recently donated $5.5 billion worth of Berkshire Hathaway stock to family foundations without selling any shares, illustrating a tax-efficient giving strategy. The article extends this principle to a 72-year-old individual holding $400,000 in Berkshire stock who wishes to donate $20,000 annually to her church. It outlines three methods for charitable giving, demonstrating that donating shares directly or using a qualified charitable distribution from an IRA can significantly reduce tax liabilities compared to selling shares for cash.
Destiny Tech100 Q3FY26 Results: NAV rises 11.7% QoQ to $38.32
Destiny Tech100 Inc. reported a net asset value (NAV) of $38.32 per share for the quarter ended September 30, 2026, marking an 11.7% increase from the previous quarter's $34.30. The fund's investment portfolio, consisting of privately-held technology companies and short-term investments, had an aggregate fair value of approximately $1.84 billion. This significant NAV rise indicates positive valuation adjustments within its private technology holdings.
Sachem Capital Q3 Results: Loss narrows to $0.07, sales beat estimates
Sachem Capital Corp reported a narrower-than-expected Q3 loss of $0.07 per share, beating the consensus estimate by 30%. The company's quarterly sales reached $9.053 million, surpassing estimates by 5.57%, despite a 24.56% year-over-year decline in revenue. This indicates effective cost management or other income factors offsetting reduced sales volume.
CMS gives states another 6 months to implement Medicaid work requirements
The CMS has granted states a six-month delay, until June 30, to implement Medicaid work requirements, allowing more time to prepare systems for eligibility checks. States can apply for this "hold harmless" option by December 11, extending the original January 1 deadline. This decision comes after states struggled with IT system readiness and pushed back against the requirements, with some industry groups praising the delay to prevent beneficiaries from losing coverage due to administrative issues.
OpenAI Unveils AI Agent That Directly Operates Hospital Systems, Adopted by CVS and Cigna
OpenAI has launched a "ChatGPT for Healthcare" update featuring an AI agent capable of directly interacting with hospital and insurer software to automate administrative tasks like preparing MRI orders and prior-authorization forms. This agent has been adopted by CVS Health and Cigna Healthcare, significantly reducing backlogs and information search times. The update also includes improved clinical search features and expanded plugin support from various healthcare companies, shifting medical AI's focus from diagnostic assistance to administrative automation.
American Financial Group stock hits 52-week low at 19.2 USD
American Financial Group Inc. (AFGD) stock has fallen to a 52-week low of $19.2, down from a high of $22.92, though shares are currently trading at $19.33. InvestingPro analysis indicates the stock is oversold, potentially presenting a buying opportunity, given its 7.21% dividend yield and a P/E ratio of 12.6, despite a -3.14% return over the past year.
Seth Klarman’s Baupost Group Takes New Position in Honeywell Aerospace in Q3
Seth Klarman's Baupost Group disclosed its Q3 2026 portfolio changes, revealing new positions in Honeywell Aerospace and SiteOne Landscape Supply. The hedge fund also exited several positions, including Teleflex Inc and Norwegian Cruise Line Holdings, while adjusting its holdings in existing stocks such as Axalta Coating Systems and Union Pacific Corp. Amazon.com Inc remained its largest holding.
Molina Healthcare Jumps 7.5% Amid Sector-Wide Rally
Molina Healthcare (MOH) shares surged 7.5% to $225.25 on November 16, 2026, as part of a broader rally in managed care stocks, pushing its market capitalization to $11.8 billion. Other sector peers like Elevance Health (ELV) and Centene Corporation (CNC) also saw gains. The rally suggests strong investor interest in the healthcare plans sector, though no specific company catalyst was identified for Molina's outperformance, indicating macro factors or portfolio repositioning as potential drivers.
Molina Healthcare climbs 8% as sector moves higher (MOH:NYSE)
Molina Healthcare (MOH) shares increased over 8% on Monday, adding $16.98 to reach $226.47. This rise occurred as other managed healthcare providers like CNC and ELV also saw gains, with HUM, UNH, and CVS climbing as well. The article notes that the content was AI-generated and intended for informational purposes.
Florida fines 13 pharmacy benefit managers $12.66 million, including a CVS-affiliated company
Florida has levied $12.66 million in fines against 13 pharmacy benefit managers (PBMs), including a CVS Health company, for violating state laws related to fair pricing, network adequacy, and pharmacy contracts. These penalties are the result of market conduct examinations under Florida's Prescription Drug Reform Act, with several companies contesting the findings. Regulators are pressing for greater transparency and accountability from PBMs, warning of further enforcement for non-cooperation.
Is Cigna Group (CI) Below Fair Value On Mixed Q3 2026 Earnings?
Cigna Group (CI) released mixed Q3 2026 earnings, reporting higher sales and revenue but lower net income and EPS. Despite recent share gains, the stock trades below analyst targets and appears significantly undervalued, with a narrative fair value estimate of $636.28 against its closing price of $297.00. The perceived undervaluation is attributed to market concerns regarding political hostility towards PBMs, regulatory monitoring of Express Scripts, and other operational uncertainties, reducing the actionable margin of safety.
Molina Healthcare chief legal officer sells $1.62M in shares
Molina Healthcare's chief legal officer, Jeff D. Barlow, recently sold 8,000 shares of company stock for a total of $1.62 million. This transaction occurred on November 10, 2026, after the stock saw a 52% return over the past year. Despite the sale, Barlow retains a significant number of shares, with more scheduled to vest in the coming years.
More than 200 New York social adult day care centers will lose Anthem coverage, leaving families seeking alternatives
Anthem Blue Cross and Blue Shield is terminating contracts with over 200 social adult day care centers in New York, effective between January 1 and May 1, amidst a statewide crackdown on Medicaid and Medicare fraud. While Anthem has not accused these specific centers of fraud, the decision leaves many elderly adults and their caregivers scrambling to find alternative in-network services. State and federal investigations into fraud in the social adult day care sector are ongoing, with a moratorium on new providers in place until January 2027.
3 US Defensive Dividend Stocks For Higher Rates and Steady Cash Flow
This article identifies three US large-cap defensive dividend stocks – Elevance Health (ELV), Becton Dickinson (BDX), and Cigna Group (CI) – that are well-positioned for an environment of higher interest rates due to their steady cash flows and essential services. These companies operate in healthcare, providing recurring revenue through premiums, medical supplies, and pharmacy benefits, which support consistent dividend payments. The analysis also briefly touches on potential challenges each company might face, such as rising utilization costs or pricing pressures.
Elevance Health Targets 12% Earnings Growth in 2027 as Insurance Margins Recover
Elevance Health expects adjusted earnings per share to grow at least 12% in 2027, building on a 2026 baseline of $26.75. This growth is anticipated due to improving health insurance margins, disciplined pricing, and expansion in its Carelon pharmacy and clinical services businesses. The company foresees Medicaid margins recovering from a 2026 low point, improved Medicare Advantage margins, and strategic growth opportunities for Carelon.
UnitedHealth releases 'independent review' of its medical policies
UnitedHealth Group has completed an "independent review" of its medical policy development and maintenance processes, initiated due to leadership changes and investor lawsuits. The report by FTI Consulting and Rubrum Advising found UnitedHealthcare has a strong, industry-leading approach, though it identified areas for improvement in documentation. CEO Steve Hemsley welcomed the findings, stating they will be used to further strengthen processes.
Healthy Birth Day, Inc. and Elevance Health Foundation Expand Stillbirth Prevention Partnership To 11 States
Healthy Birth Day, Inc. announced a new $1.3 million grant from Elevance Health Foundation to expand its "Count the Kicks" stillbirth prevention program to 11 states. This funding will support education, training, tools, and awareness campaigns, aiming to make fetal movement monitoring a standard of care. The partnership seeks to improve maternal and child health outcomes by teaching expectant parents a simple method for understanding their baby’s normal movement patterns, which has already been credited with saving lives.
Three indicative grades cover Elevance Health’s new securities filing.
AM Best has assigned indicative Long-Term Issue Credit Ratings to Elevance Health, Inc.'s new shelf registration, including "bbb+" for senior unsecured issues, "bbb" for subordinated issues, and "bbb-" for preferred stock issues. The outlook for these ratings is stable, and AM Best concurrently withdrew the ratings of the previous, expired shelf registration. The company maintains strong financial flexibility, liquidity, risk-adjusted capitalization, and operating results, with financial leverage measured at 40.8% as of September 30, 2026.
AM Best Assigns Indicative Issue Credit Ratings to Elevance Health, Inc.’s New Shelf Registration
AM Best has assigned indicative Long-Term Issue Credit Ratings to Elevance Health, Inc.'s new shelf registration, maintaining a stable outlook. The ratings include "bbb+" for senior unsecured issues, "bbb" for subordinated issues, and "bbb-" for preferred stock issues. Elevance Health's financial leverage, earnings coverage, risk-adjusted capitalization, and liquidity remain strong, supporting the assigned ratings.
Healthcare providers & services stocks Q3 results: Benchmarking McKesson
This article benchmarks McKesson (MCK) and its peers' Q3 performance within the healthcare providers & services sector. McKesson reported solid revenue and EPS beats, while LifeStance Health Group (LFST) had the best Q3 with strong revenue growth and raised guidance. Brookdale (BKD) experienced the weakest Q3 with declining revenues and a significant stock drop.
Healthy Birth Day, Inc. and Elevance Health Foundation Expand Stillbirth Prevention Partnership To 11 States
Healthy Birth Day, Inc. and Elevance Health Foundation have expanded their stillbirth prevention partnership to 11 states with a new $1.3 million grant. The "Count the Kicks" program teaches expectant parents to monitor fetal movements, aiming to make this an evidence-based standard of care. This expansion will provide education, training, and awareness campaigns, potentially reaching 900,000 people and helping to reduce stillbirth rates, especially among disproportionately affected communities.
Healthy Birth Day, Inc. and Elevance Health Foundation Expand Stillbirth Prevention Partnership To 11 States
Healthy Birth Day, Inc. announced a new $1.3 million grant from Elevance Health Foundation to expand its evidence-based Count the Kicks stillbirth prevention program to 11 additional states. The program aims to make fetal movement monitoring a standard of care, providing free educational materials and training to healthcare professionals and expectant parents. This expansion is projected to reach 900,000 people and has already been credited by 14 families for helping ensure safe deliveries, addressing a national public health crisis that disproportionately affects certain communities.
What Avantis U.S. Large Cap Value ETF (AVLV) Bought: AT&T Leads on Tuesday
On Tuesday, November 10, the Avantis U.S. Large Cap Value ETF (AVLV) was the sole ETF engaged in buying activity, acquiring $424.8 million in stock and selling nothing. The fund increased 161 positions, with its largest buys by dollar value being AT&T (T) at $15.8 million, Newmont (NEM) at $14.8 million, and Micron Technology (MU) at $14.7 million. AVLV holds 275 stocks, with significant allocations to Financial Services, Consumer Cyclical, and Energy sectors, primarily focusing on large-cap companies.
Elevance Health stock faces 2027 test after raised 2026 outlook
Elevance Health reported stronger-than-expected third-quarter results and raised its full-year 2026 outlook, with adjusted EPS guidance now at least $29.00 and operating cash flow at least $6.5 billion. The company's 2027 plan starts from a higher earnings baseline, targeting at least 12% adjusted EPS growth, making medical-cost control and membership trends crucial. Despite a decline in medical membership, improved operating performance in Carelon and Health Benefits segments contributed to the positive financial adjustments.
CVS Health earns global recognition for industry-leading AI and technology innovation
CVS Health has received seven Stevie Awards for its innovative AI and technology projects, which span clinical operations, disaster response, and workforce training. These awards acknowledge the company's past efforts in areas such as prior authorization automation, a patent-pending drone network for medical supply delivery, and AI bias toolkits. The recognition highlights CVS Health's commitment to leveraging technology to improve patient services and operational efficiency, although the announcement does not bear directly on the company's financial results.
With about $7 a share in net unfavorable items, Elevance Health (ELV) expects to reaffirm its 2026 outlook.
Elevance Health (ELV) announced that its officers expect to reaffirm the full-year 2026 shareholders’ earnings guidance of at least $22.00 per diluted share during upcoming meetings with investors and analysts. This guidance includes approximately $7.00 per diluted share of net unfavorable items. Excluding these items, the adjusted earnings are projected to be at least $29.00 per diluted share, and the company also expects to reaffirm its full-year benefit expense ratio guidance of 90.2%, plus or minus 50 basis points.
Global Net Lease stock hits 52-week low at 6.79 USD
Global Net Lease Inc. (GNL) stock has fallen to a 52-week low of $6.79, reflecting a 1-year decline of 13.37%, though it offers a significant dividend yield of 11.06%. Despite appearing overvalued by InvestingPro analysis, its RSI suggests it's in oversold territory. The company recently reported a wider-than-expected Q3 loss but raised its full-year cash earnings outlook, continuing to focus on asset sales and share buybacks.
The $449 Billion Quarter: America’s Biggest Health Insurers May Be Back on Top
The nation's largest health insurers reported a record $449 billion in revenue and $9.2 billion in profits in Q3, exceeding analyst expectations. This growth was driven by strategies focused on charging more, covering less, and shifting financial risk, rather than expanding access or improving services. While investors celebrate, these practices raise concerns about healthcare affordability and accessibility for Americans, as evidenced by declining enrollment in fully insured plans and rising costs for consumers.
How Did UnitedHealth Beat Forecasts and Raise Guidance in Q3 Results?
UnitedHealth Group (NYSE:UNH) reported strong Q3 results on October 13, surpassing analyst forecasts for adjusted earnings per share and improving its medical care ratio. While total membership was slightly below expectations, reflecting a strategy to prioritize profitable business, the company raised its full-year earnings outlook. The positive report offers insights into the broader healthcare sector, though regulatory scrutiny and ongoing medical cost trends remain factors to monitor.
Surgery Partners reportedly rejected UnitedHealth Group’s bid
Surgery Partners has reportedly rejected an unsolicited $28 per share bid from UnitedHealth Group due to regulatory risks and potential closing delays. Instead, Surgery Partners amended its agreement with HealthSpan Partners, an affiliate of Bon Secours Mercy Health, raising the all-cash offer to $25 per share, valuing the deal at approximately $6 billion. The original merger announcement with HealthSpan Partners was made on October 26, with an expected close in the first quarter of 2027.